Skip to main content

Hernandez Marlow's Form 4 filing

Cano Health, Inc. (CANO) · filed Aug 23, 2021

Accession no.
0000899243-21-033963
Filed
Aug 23, 2021
Trade date
Aug 18-20, 2021
Filing delay
5 daysLate
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 3 non-derivative transactions and 3 derivative transactions. Open-market purchases total $478.4K. It was filed 5 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Hernandez MarlowCIK 0001865483Director, Officer (CEO and President)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 18, 2021Class A Common StockPPurchaseAcquired+11,900$9.82F1+$116,858221,900Direct
Aug 19, 2021Class A Common StockPPurchaseAcquired+25,000$10.38F2+$259,500246,900Direct
Aug 20, 2021Class A Common StockPPurchaseAcquired+10,000$10.20+$102,000256,900Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 18, 2021Class A Common StockPPurchaseAcquired+1,832$2.30+$4,213.6251,832Direct
Aug 19, 2021Class A Common StockPPurchaseAcquired+15,000$2.89F3+$43,350266,832Direct
Aug 20, 2021Class A Common StockPPurchaseAcquired+5,000$2.75+$13,750271,832Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.40 to $9.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1)-(3) to this Form 4.

Referenced by the price of 1 transaction in Table I.

F2

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.25 to $10.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1)-(3) to this Form 4.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted average price. These warrants were purchased in multiple transactions at prices ranging from $2.86 to $2.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1)-(3) to this Form 4.

Referenced by the price of 1 transaction in Table II.

Read the full filing on SEC EDGAR (opens in a new tab)